NewEdge Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.35M | Buy |
10,723
+3,093
| +41% | +$389K | 0.01% | 1125 |
|
|
2025
Q1 | $844K | Buy |
7,630
+2,747
| +56% | +$304K | 0.01% | 1278 |
|
|
2024
Q4 | $667K | Sell |
4,883
-169
| -3% | -$23.1K | ﹤0.01% | 1382 |
|
|
2024
Q3 | $582K | Buy |
5,052
+1,959
| +63% | +$226K | ﹤0.01% | 1379 |
|
|
2024
Q2 | $426K | Buy |
3,093
+213
| +7% | +$29.3K | ﹤0.01% | 1507 |
|
|
2024
Q1 | $397K | Buy |
2,880
+2,428
| +537% | +$335K | ﹤0.01% | 1478 |
|
|
2023
Q4 | $59.6K | Buy |
452
+404
| +842% | +$53.2K | ﹤0.01% | 2172 |
|
|
2023
Q3 | $5.4K | Hold |
48
| – | – | ﹤0.01% | 2784 |
|
|
2023
Q2 | $4.53K | Sell |
48
-413
| -90% | -$38.9K | ﹤0.01% | 2855 |
|
|
2023
Q1 | $46.7K | Sell |
461
-13,474
| -97% | -$1.36M | ﹤0.01% | 2035 |
|
|
2022
Q4 | $1.61M | Buy |
+13,935
| New | +$1.61M | 0.04% | 369 |
|